Clinical trials: Infliximab
Crohn Disease, Ulcerative Colitis
National Observational Study On The Use Of Inflectra™ An Infliximab Biosimilar In Real Life
National, prospective, multicentre observational study designed for eligible patients treated with Inflectra. Its objectives are to describe under real conditions of use, the profile of patients treated with Inflectra and the…
- Conditions
- Crohn Disease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis
- Trial name
- ReFLECT (NCT02925338)
- Testing
- QOL questionaire
- Where
- 67 sites in France
- Volunteers
- 1,431 people
- Sponsor
- Pfizer
Psoriasis Vulgaris, Psoriasis Arthropathica
Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Psoriasis)
To collect information on the safety and effectiveness of Infliximab BS for Intravenous Drip Infusion 100 mg "Pfizer" against psoriasis vulgaris, psoriasis arthropathica, pustular psoriasis, or erythrodermic psoriasis under…
- Conditions
- Psoriasis Vulgaris, Psoriasis Arthropathica, Pustular Psoriasis, Erythrodermic Psoriasis
- Trial name
- NCT03885089
- Testing
- Infliximab [infliximab biosimilar 3]
- Where
- Japan
- Volunteers
- 10 people
- Sponsor
- Pfizer
Ulcerative Colitis
Infliximab Accelerated Induction in Moderate to Severe Pediatric UC
Objectives: To examine the effect of accelerated infliximab induction in children with moderate to severe UC. Design: A multi-center, prospective, randomized, open label study. Setting: Pediatric gastroenterology centers.
- Trial name
- INDUCE (NCT03209232)
- Testing
- Infliximab
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Schneider Children's Medical Center, Israel
Inflammatory Bowel Disease, Crohn's Disease
IDeaL Pilot Study - Infliximab Dose to Level: Pilot Study
Crohn's disease (CD) is a lifelong condition of inflammation in the bowel. CD can affect any part of the gastrointestinal tract from mouth to anus.
- Trial name
- IDeaL (NCT02847884)
- Testing
- Infliximab
- Where
- 2 sites in Canada
- Volunteers
- 28 people
- Sponsor
- University of Alberta
Crohn's Disease
Infliximab Top-down in Pediatric Crohn
The purpose of this study is to determine whether a top-down treatment approach, prescribing infliximab and azathioprine at diagnose, yields better outcome in comparison to the usual step-up treatment approach, starting with…
- Trial name
- ITSKids (NCT01880307)
- Testing
- Azathioprine, Infliximab, Prednisolon
- Where
- 2 sites in Italy, Netherlands
- Volunteers
- 13 people
- Sponsor
- Erasmus Medical Center
Chronic Inflammatory Disease
Infusion Related Reactions in Patients Receiving Infliximab
Infliximab is the active ingredient in a drug currently sold by the trade names Remicade, Remsima and Inflectra. Infliximab neutralizes tumor necrosis factor (TNF) α, a chemical messenger (cytokine) in the immune system, and…
- Trial name
- NCT02332460
- Where
- Norway
- Volunteers
- 125 people
- Sponsor
- Haukeland University Hospital
Inflammatory Bowel Diseases
Biomarkers of Anti-TNF Treatment in Inflammatory Bowel Disease (IBD)
Anti-TNF treatment (infliximab (IFX), adalimumab (ADA)) has become standard therapy for refractory pediatric and adult Crohn's disease (CD) patients, and is used for the induction (primary response) and maintenance of remission.
- Trial name
- NCT01971970
- Testing
- Infliximab, Adalimumab
- Where
- Netherlands
- Volunteers
- 45 people
- Sponsor
- Erasmus Medical Center
Hidradenitis Suppurativa
Study to Assess the Safety and Efficacy of Infliximab to Treat Hidradenitis Suppurtativa
A study to assess the safety and efficacy of the IV drug infliximab for the treatment of hidradenitis suppurativa
- Trial name
- HS2006 (NCT00795574)
- Testing
- infliximab
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Florida Academic Dermatology Centers
Pediatric Inflammatory Bowel Disease
Durability and Tolerability of Infliximab in Pediatric Inflammatory Bowel Disease Patients: A 10 Year Single Center Experience
There is little data published on the long term durability of infliximab in pediatric patients. In particular a focus on durable remission, frequency of dose/frequency change and switch within class.
- Trial name
- NCT01490528
- Volunteers
- 200 people
- Sponsor
- Cedars-Sinai Medical Center
Crohn's Diseases, Crohn's Disease in Pediatric Patient
The Efficacy and Safety of Infliximab Combination With Azathioprine in Crohn's Disease in Children
The goal of this clinical trial is to investigate whether there are significant differences in the efficacy of infliximab monotherapy and combined azathioprine therapy in treating pediatric Crohn's disease, as well as whether…
- Trial name
- NCT07424040
- Testing
- Infliximab combined with azathioprine therapy, Infliximab monotherapy
- Where
- 4 sites in China
- Volunteers
- 154 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Arthritis, Rheumatoid
Remicade Safety Line (Study P03236)(COMPLETED)
The goal of this study is to implement instruments that would increase the treating physician's awareness of the necessary tuberculosis screening when starting a new patient on infliximab (Remicade) therapy who has not reacted…
- Trial name
- NCT00748826
- Testing
- Infliximab
- Volunteers
- 576 people
- Sponsor
- Merck Sharp & Dohme LLC
Crohn's Disease
Remicade® Crohn's Disease Registry Across Canada (Study P02793)
This registry is a multi-center, prospective, observational program that will gather and analyze data on subjects with Crohn's disease being treated with Remicade® as per approved product monograph in Canada.
- Trial name
- RemiTRAC® (NCT00755937)
- Testing
- Data collection post infusion
- Volunteers
- 556 people
- Sponsor
- Merck Sharp & Dohme LLC
Uveitis
A Clinical Trial of Infliximab for Uveitis
This project is designed to test the hypothesis that inhibition of binding between tumor necrosis factor alpha (TNF-alpha) and its receptors using Remicade (infliximab, chimeric mouse/human IgG1K monoclonal antibody directed…
- Trial name
- NCT00273390
- Testing
- Remicade (infliximab)
- Volunteers
- 32 people
- Sponsor
- Oregon Health and Science University
Crohn's Disease
Salvage Therapy With High/Low Methotrexate for Loss of Response to Infliximab Dose Escalation
The goal of the present study is to evaluate if addition of methotrexate can restore remission after loss of response to infliximab after dose escalation.
- Trial name
- NCT02269358
- Testing
- METHOTREXATE
- Where
- Israel
- Volunteers
- 22 people
- Sponsor
- Prof. Arie Levine
Kawasaki Disease Refractory to Initial Therapy With Intravenous Immunoglobulin
Clinical Study of TA-650 in Patients With Refractory Kawasaki Disease
The purpose of this study is to evaluate the efficacy and safety of TA-650 in comparison with a control drug Polyethylene Glycol-treated Human Immunoglobulin (VGIH) in patients with Kawasaki disease refractory to initial therapy…
- Trial name
- NCT01596335
- Testing
- TA-650, Polyethylene Glycol-treated Human Immunoglobulin (VGIH)
- Where
- 8 sites in Japan
- Volunteers
- 31 people
- Sponsor
- Tanabe Pharma Corporation
Spondylitis, Ankylosing
Investigation of 9 Consecutive Remicade Infusions in Ankylosing Spondylitis in Austria (Study P04044)(COMPLETED)
This is a prospective, open-label, 1-arm, multicenter observational study to determine the dose and time span of Remicade between infusions for ankylosing spondylitis (AS).
- Trial name
- NCT00725543
- Testing
- Infliximab
- Volunteers
- 358 people
- Sponsor
- Merck Sharp & Dohme LLC
Plaque Psoriasis, Psoriatic Arthritis
A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of TA-650 at increased dose of 10 mg/kg every 8 weeks in patients with psoriasis in whom effect of the treatment was confirmed after the treatment…
- Conditions
- Plaque Psoriasis, Psoriatic Arthritis, Pustular Psoriasis (Excluding a Localized), Psoriatic Erythroderma
- Trial name
- NCT01680159
- Testing
- TA-650
- Where
- 7 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Tanabe Pharma Corporation
Behcet's Disease, Vasculitis
Induction Therapy With Anti-TNFα vs Cyclophosphamide in Severe Behçet Disease
Behçet's disease (BD) is a systemic vasculitis of arterial and venous vessels of any size, involving young patients (from 15 to 45 years). BD significantly increases morbidity and mortality.
- Trial name
- ITAC (NCT03371095)
- Testing
- Infliximab, Cyclophosphamide
- Where
- 27 sites in France
- Volunteers
- 53 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Crohn's Disease
The Effect of a Probiotic Preparation (VSL#3) Plus Infliximab in Children With Crohn's Disease
The purpose was to evaluate as to whether administration of infliximab of 12 week interval with supplementary VSL#3 is more effective or at least of similar efficacy when compared to conventional administration of infliximab only…
- Trial name
- NCT01548014
- Testing
- VSL#3
- Where
- South Korea
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Samsung Medical Center
Crohn's Disease, Ulcerative Colitis
Infliximab Biosimilar "Pfizer" Drug Use Investigation (Crohn's Disease or Ulcerative Colitis)
To collect information on the safety and effectiveness of Infliximab BS for Intravenous Drip Infusion 100 mg "Pfizer" against Crohn's disease or ulcerative colitis under actual status of use.
- Trial name
- NCT03884439
- Testing
- Infliximab [infliximab biosimilar 3]
- Where
- Japan
- Volunteers
- 428 people
- Sponsor
- Pfizer